Using PET Scans To Monitor Cancer Cells' Activity And Predict Who Will Develop Alzheimer's, Othe...( s have indicated that PET detects the m...)

Serial scans are used to follow the progressive spreading of the disease throughout an increasing number of structures within the brain, he explained. A similar approach is taken with Parkinson's disease, except fluorine-18 labeled L-DOPA is used to identify the early abnormalities of dopamine synthesis at a time of mild symptoms and normal structural imaging studies. PET is now being used to assess therapeutic interventions that would seek to stop or reverse the metabolic alterations on these degenerative diseases, according to Phelps.

On January 1, he said, the federal government began reimbursing physicians who used PET scans for diagnosing and staging the degree of metastasis in lung cancer. The government has also agreed to perform expedited reviews of 12 other clinical indications for PET. In addition, the Food, Drug and Cosmetic Act was changed this year in a bill sponsored by Senator Stevens, Chair of Appropriations, that directs the FDA to design a new review and regulatory approach that takes into account the special properties of PET, and that while this takes place, the US Pharmacopoeia will be employed as the legal standard of FDA approval, Phelps said. The USP has approved the radiotracers mentioned above for numerous diagnostic indications in cancer, heart disease and neurological diseases such as Alzheimer's, Parkinson's, stroke and epilepsy. Phelps points to this as evidence that advancement in radiotracer chemistry is allowing PET to move more fully in the everyday medical practice.

'"/>

Contact: Nancy Blount
n_blount@acs.org
202/872-4440
American Chemical Society
30-Mar-1998